Recombinant blood products and therapeutic enzymes - Pharmaceutical Biotechnology: Concepts and Aapplications - page 369

Articles
Plasma proteins, including coagulation factors
Bowen, D. 2002. Haemophilia a and haemophilia b: molecular insights. Journal of Clinical Pathology - Molecu-
lar Pathology 55 (1), 1-18.
Chuang, V.T., Kragh-Hansen, U., and Otagiri, M. 2002. Pharmaceutical strategies utilizing recombinant human
serum albumin . Pharmaceutical Research 19 (5), 569-577.
Cervenakova, L., Brown, P., Hammond, D.J., Lee, C.A., and Saenko, E.L. 2002. Factor VIII and transmissible
spongiform encephalopathy: the case for safety. Haemophilia 8 (2), 63-75.
DeLoughrey, T. 2006. Management of bleeding emergencies: when to use recombinant activated factor VII. Ex-
pert Opinion on Pharmacotherapy 7 (1), 25-34.
Farrugia, A. 2004. Safety and supply of haemophilia products: worldwide perspectives. Haemophilia 10 (4),
327-333.
Federici, A. and Mannucci, P. 2002. Advances in the genetics and treatment of von Willebrand disease. Current
Opinion in Pediatrics 14 (1), 23-33.
Giangrande, P. 2005. Haemophila B: Christmas disease. Expert Opinion on Pharmacotherapy 6 (9), 1517-1524.
Graw, J., Brackmann, H.H., Oldenburg, J., Schneppenheim, R., Spannagl, M., and Schwaab, R. 2005. Haemo-
philia A: from mutation analysis to new therapies. Nature Reviews Genetics 6 (6), 488-501.
Kingdon, H. and Lundblad, R. 2002. An adventure in biotechnology: the development of haemophilia A
therapeutics - from whole blood transfusion to recombinant DNA technology to gene therapy. Biotechnology
and Applied Biochemistry 35 , 141-148.
Klinge, J., Ananyeva, N.M., Hauser, C.A., and Saenko, E.L. 2002. Hemophilia A - from basic science to clinical
practice. Seminiars in Thrombosis and Hemostasis 28 (3), 309-321.
Legaz, M.E., Schmer, G., Counts, R.B., and Davie, E.W. 1973. Isolation and characterization of human factor
VIII (antihaemophilic factor). Journal of Biological Chemistry 248 , 3946-3955.
Nicholson, J.P., Wolmarans, M.R., and Park, G.R. 2000. The role of albumin in critical illness . British Journal
of Anaesthesia 85 (4), 599-610.
Ogden, J. 1992. Recombinant haemoglobin in the development of red blood cell substitutes. Tren ds in Biotech nol-
ogy 10 , 91-95.
Winslow, R. 2000. Blood substitutes: refocusing an elusive goal. British Journal of Haematology 111 (2), 387-396.
Anticoagulants and related substances
Bates, S. and Weitz, J. 2005. New anticoagulants: beyond heparin, low molecular weight heparin and warfarin.
British Journal of Pharmacology 144 (8), 1017-1028.
Dahlback, A. and Villotreix, B. 2005. The anticoagulant protein C pathway. FEBS Letters 579 (15), 3310 -3316.
De Kort, M., Buijsman, R.C., and van Boeckel, C.A. 2005. Synthetic heparin derivatives as new anticoagulant
drugs. Drug Discovery Today 10 (11), 769-779.
Dodt, J. 1995. Anti-coagulatory substances of bloodsucking animals: from hirudin to hirudin mimetics. Ange-
wandte Chemie International Edition in English 34 , 867-880.
Eldor, A., Orevi, M., and Rigbi, M. 1996. The role of the leech in medical therapeutics. Blood Reviews 10 (4),
201-209.
Fischer, K. 2004. The role of recombinant hirudins in the management of thrombotic disorders. Biodrugs 18 (4),
235-268.
Linkins, L. and Weitz, J. 2005. New anticoagulant therapy. Annual Review of Medicine 56 , 63-77.
O'Brien, L.A., Gupta, A., and Grinnell, B.W. 2006. Activated protein C and sepsis. Frontiers in Bioscience 11 ,
676-698.